Edmond DE Rothschild Holding S.A. Invests $4.25 Million in Denali Therapeutics Inc. $DNLI

Key Points

• Edmond DE Rothschild Holding S.A. acquired 165,080 Denali Therapeutics shares worth approximately $4.25 million, joining other institutional investors that recently increased their positions. Institutions and hedge funds collectively own 92.92% of DNLI.
• Denali reported a quarterly loss of $0.68 per share, missing analysts’ $0.51-loss estimate, while revenue of $3.60 million exceeded expectations. Analysts project a full-year loss of $2.59 per share.
• DNLI has a consensus “Moderate Buy” rating and an average price target of $35.92 versus a recent price of $25.69, though analyst opinions range from Buy to Sell.

Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 165,080 shares of the company's stock, valued at approximately $4,246,000. Edmond DE Rothschild Holding S.A. owned approximately 0.10% of Denali Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Denali Therapeutics in the second quarter valued at $360,759,000. Norges Bank purchased a new position in Denali Therapeutics in the 4th quarter valued at about $84,525,000. ADAR1 Capital Management LLC lifted its position in shares of Denali Therapeutics by 3,490.9% in the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company's stock valued at $35,932,000 after acquiring an additional 1,819,339 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Denali Therapeutics by 77.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company's stock worth $63,329,000 after purchasing an additional 1,672,098 shares during the last quarter. Finally, Temasek Holdings Private Ltd boosted its position in Denali Therapeutics by 30.9% during the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company's stock worth $115,784,000 after acquiring an additional 1,657,142 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Insider Activity at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the sale, the insider owned 281,763 shares of the company's stock, valued at $7,063,798.41. The trade was a 1.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 9.70% of the company's stock.

Denali Therapeutics Price Performance

DNLI stock opened at $25.69 on Thursday. Denali Therapeutics Inc. has a twelve month low of $12.58 and a twelve month high of $27.30. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $4.11 billion, a P/E ratio of -9.05 and a beta of 1.01. The business has a 50 day simple moving average of $24.31 and a 200-day simple moving average of $21.56.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to analysts' expectations of $2.15 million. During the same quarter in the previous year, the business earned ($0.72) EPS. As a group, equities analysts anticipate that Denali Therapeutics Inc. will post -2.59 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on DNLI. Robert W. Baird set a $34.00 price target on Denali Therapeutics in a report on Friday, August 7th. BTIG Research reiterated a "buy" rating and set a $39.00 price target on shares of Denali Therapeutics in a report on Monday, May 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Denali Therapeutics in a report on Friday, July 17th. Wall Street Zen raised Denali Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, UBS Group upped their price objective on Denali Therapeutics from $25.00 to $34.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $35.92.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source